Shelia Violette

Shelia Violette, co-founder, Chief Scientific Officer and President of Research of Q32 Bio, is a scientific leader in the field of inflammation, autoimmunity and fibrosis. In her more than 20 years of industry experience advancing programs from early research to clinical development, Shelia has provided strategic and operational leadership to multi-disciplinary teams of scientists, led several research and early clinical programs, and authored more than 90 manuscripts and patents. Prior to co-founding Q32 Bio, she was an Entrepreneur in Residence at Atlas Venture and is an Adjunct Associate Professor in the Department of Internal Medicine at the Yale School of Medicine. Prior to her role at Atlas, Shelia served in leadership roles in the Immunology Research group at Biogen, joining Stromedix as Vice President of Research and returning to Biogen as Vice President of Research, spearheading the tissue injury and fibrosis therapeutic area. She also has directed research and led therapeutic programs at several biotechnology companies including Repligen and Ariad. She received her Ph.D. in Pharmacology from Yale University.